The B.A.C.K. Center
Welcome,         Profile    Billing    Logout  
 2 Trials 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
King, Lisa
ON TARGET DM, NCT05073692: Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Recruiting
N/A
270000
US
SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
Kaiser Permanente, Geisinger Clinic, Henry Ford Health System, HealthPartners Institute, Patient-Centered Outcomes Research Institute
Type 2 Diabetes Mellitus, Cardiovascular Diseases
12/24
08/25

Download Options